MetaCap

Treace Medical Concepts Inc. (TMCI)

NASDAQ: TMCIHealth CareMedical/Dental InstrumentsUSD

4.31-0.04 (-0.92%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TMCI stock chart

Technical analysis

Key statistics

All statistics
Market cap
$282.56M
EPS (TTM)
-$0.85
52-week range
1.17 – 5.44
Day range
4.17 – 4.43
Volume / Avg
232.75K / 267.11K
Beta
—

52-week range

$1.17$5.44

TMCI stock today

Treace Medical Concepts (TMCI) closed at $4.31 on Nov 20, down 0.92% (-$0.04), versus the S&P 500's 3.70% decline. Shares are 20.8% below their 52-week high of $5.44, set on Nov 11, 2026 and 268.4% above the 52-week low of $1.17, in the middle of the past year's range. TMCI is up 75.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 50.7%.

Treace Medical Concepts has posted a net loss over the last twelve months (EPS of -$0.85), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Treace Medical Concepts

Company profile

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant.

Industry
Medical/Dental Instruments
CEO
Mr. John T. Treace
Headquarters
Ponte Vedra, FL
Employees
450
IPO year
2021
Website
treace.com

Financial highlights

Full financials

In fiscal 2025, Treace Medical Concepts generated $212.7 million in revenue, up 1.6% from fiscal 2024, its 6th consecutive year of revenue growth. Treace Medical Concepts reported a net loss of $59.0 million, compared with a loss of $55.7 million a year earlier. Gross margin was 79.8% (down from 80.4%) and operating margin -25.5%.

Treace Medical Concepts annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$212.69M$209.36M$187.12M$141.84M$94.42M
Growth+1.59%+11.89%+31.92%+50.22%+64.59%
Net income$-59.00M$-55.74M$-49.53M$-42.81M$-20.55M
EPS (diluted)$-0.93$-0.90$-0.81$-0.77$-0.43

Analyst forecast

Forecast

Consensus (5 analysts)

buy

Avg. price target

$6.17+43.16%

  • Strong buy 0
  • Buy 2
  • Hold 2
  • Sell 0
  • Strong sell 1

Target range

Low $5.00High $7.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 6, 2026
EPS actual vs est.
$-0.19 vs $-0.26
Surprise
+26.92%

TMCI news

All TMCI news

Treace Medical Concepts peers

Health Care sector
TMCI peer companies
CompanyPrice% ChgMarket capCompare
INFUInfuSystems Holdings Inc.14.35+2.06%$287.48Mvs TMCI
NPCENeuropace Inc.7.95-2.33%$273.89Mvs TMCI
SSIISS Innovations International Inc.1.27-0.78%$254.86Mvs TMCI
OFIXOrthofix Medical Inc.6.07-4.26%$247.41Mvs TMCI
OSUROraSure Technologies Inc.3.46-4.16%$238.90Mvs TMCI
PROFProfound Medical Corp.6.38-3.19%$233.68Mvs TMCI
EMBCEmbecta Corp.6.02-2.75%$341.09Mvs TMCI
BWAYBrainsWay Ltd. ADR8.48-2.86%$341.35Mvs TMCI

Indexes, lists and sector

Treace Medical Concepts stock FAQ

What is Treace Medical Concepts's stock price today?

TMCI last traded at $4.31 as of Nov 20, 4:00 PM EST, down 0.92% on the day. Prices are delayed at least 15 minutes.

Who is Treace Medical Concepts's CEO?

Mr. John T. Treace is the chief executive officer of Treace Medical Concepts Inc., which has about 450 employees.

What is the TMCI 52-week high?

The 52-week high for TMCI is $5.44 and the 52-week low is $1.17. The stock is currently 20.8% below its high.

Compare TMCI